William D. Chow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
William D. Chow has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hyo Bin You
Department of Neurological Surgery, Mayo Clinic, Rochester, MN 55901, USA
1 shared publication - Julian S. Rechberger
Department of Neurologic Surgery, Mayo Clinic, Rochester, USA
1 shared publication - Nicholas Kendall
Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota, USA
1 shared publication - Pournima Navalkele
Division of Oncology, Children’s Hospital of Orange County, Orange, CA 92868, USA
1 shared publication - Soumen Khatua
Department of Pediatric Hematology/Oncology, Mayo Clinic College of Medicine and Science, Rochester, USA
1 shared publication - Stephanie A. Toll
Children’s Hospital of Michigan, Central Michigan University School of Medicine, Saginaw, USA
1 shared publication
Latest Publications
- Open Access
Advances in the Repurposing and Blood–Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors
Central nervous system (CNS) tumors are the leading cause of cancer-related mortality in children, with prognosis remaining dismal for some of these malignancies. Though the past two decades have seen advancements in surgery, radiation, and targeted therapy, major unresolved hurdles continue to undermine the therapeutic efficacy. These include challenges in suboptimal drug delivery through the blood–brain barrier (BBB), marked intra-tumoral molecular heterogeneity, and the elusive tumor microenvironment. Drug repurposing or re-tasking FDA-approved drugs with evidence of penetration into the CNS, using newer methods of intracranial drug delivery facilitating optimal drug exposure, has been an area of intense research. This could be a valuable tool, as most of these agents have already gone through the lengthy process of drug development and the evaluation of safety risks and the optimal pharmacokinetic profile. They can now be used and tested in clinics with an accelerated and different approach. Conclusions: The next-generation therapeutic strategy should prioritize repurposing oncologic and non-oncologic drugs that have been used for other indication, and have demonstrated robust preclinical activity against pediatric brain tumors. In combination with novel drug delivery techniques, these drugs could hold significant therapeutic promise in pediatric neurooncology.
Open AccessAdvances in the Repurposing and Blood–Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors
Central nervous system (CNS) tumors are the leading cause of cancer-related mortality in children, with prognosis remaining dismal for some of these malignancies. Though the past two decades have seen advancements in surgery, radiation, and targeted therapy, major unresolved hurdles continue to undermine the therapeutic efficacy. These include challenges in suboptimal drug delivery through the blood–brain barrier (BBB), marked intra-tumoral molecular heterogeneity, and the elusive tumor microenvironment. Drug repurposing or re-tasking FDA-approved drugs with evidence of penetration into the CNS, using newer methods of intracranial drug delivery facilitating optimal drug exposure, has been an area of intense research. This could be a valuable tool, as most of these agents have already gone through the lengthy process of drug development and the evaluation of safety risks and the optimal pharmacokinetic profile. They can now be used and tested in clinics with an accelerated and different approach. Conclusions: The next-generation therapeutic strategy should prioritize repurposing oncologic and non-oncologic drugs that have been used for other indication, and have demonstrated robust preclinical activity against pediatric brain tumors. In combination with novel drug delivery techniques, these drugs could hold significant therapeutic promise in pediatric neurooncology.